利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

12 条记录 (耗时 0.024 秒)

    PROLIFERATED CELL LINES AND USES THEREOF
    3.
    发明申请
    PROLIFERATED CELL LINES AND USES THEREOF 有权
    增殖细胞系及其用途

    公开(公告)号：US20120148540A1

    公开(公告)日：2012-06-14

    申请号：US13267346

    申请日：2011-10-06

    申请人： THOMAS B. FREEMAN ,  Pablo Caviedes ,  Raul Caviedes ,  Paul R. Sanberg ,  Don F. Cameron

    发明人： THOMAS B. FREEMAN ,  Pablo Caviedes ,  Raul Caviedes ,  Paul R. Sanberg ,  Don F. Cameron

    IPC分类号： A61K35/12 ,  C12N5/071

    CPC分类号： A61K35/26 ,  C12N5/0018 ,  C12N2500/84 ,  C12N2502/078 ,  C12N2502/30 ,  C12N2503/02

    摘要： The subject invention pertains to tumor cell lines useful for increasing the proliferation potential of any human or animal cell in culture, thereby providing immortalized or continuous cell lines and cultures. The invention also concerns proliferation factors, and compositions containing the factors, which are capable of increasing the proliferation potential of any human or other animal cell in culture. The subject invention further pertains to a method for proliferating cells in culture by contacting cells with the proliferation factors. The proliferated cells can range in plasticity and can include, for example, blast cells, fertilized ova, non-fertilized gametes, embryonic stem cells, adult stem cells, precursor or progenitor cells, and highly specialized cells. Optionally, the cells can be induced to cease proliferation. The proliferated cells of the subject invention are useful for cell therapy, cell/gene therapy, biological production of molecules, and as in vitro models for research, toxicity testing, and drug development.

    摘要翻译： 本发明涉及可用于增加培养物中任何人或动物细胞的增殖潜力的肿瘤细胞系，从而提供永生化或连续的细胞系和培养物。 本发明还涉及增殖因子和含有因子的组合物，其能够增加培养物中任何人或其他动物细胞的增殖潜力。 本发明还涉及通过使细胞与增殖因子接触来增殖培养细胞的方法。 增殖的细胞可以在可塑性范围内，并且可以包括例如胚细胞，受精卵，非受精配子，胚胎干细胞，成体干细胞，前体或祖细胞和高度专门的细胞。 任选地，可诱导细胞停止增殖。 本发明的增殖细胞可用于细胞治疗，细胞/基因治疗，分子的生物制备，以及用于研究，毒性测试和药物开发的体外模型。

    Sertoli cells as biochambers
    4.
    发明授权
    Sertoli cells as biochambers 失效
    Sertoli细胞作为生物体

    公开(公告)号：US06790441B1

    公开(公告)日：2004-09-14

    申请号：US09593629

    申请日：2000-06-13

    申请人： Don F. Cameron ,  Paul R. Sanberg ,  Samuel Saporta ,  Joelle J. Hushen

    发明人： Don F. Cameron ,  Paul R. Sanberg ,  Samuel Saporta ,  Joelle J. Hushen

    IPC分类号： A01N6500

    CPC分类号： C12N5/0677 ,  A61K35/12 ,  C12N5/0619 ,  C12N2502/246

    摘要： According to the present invention, there is provided a biological chamber system having a biochamber defined by outer walls of Sertoli cells. Also provided is a transplantation facilitator including a biochamber. A method of making biochambers by co-culturing facilitator cells and therapeutic cells and then aggregating the facilitator celes is also provided. Also provided is a method of transplanting cells by incorporating transplant cells into a biochamber and transplanting the biochamber containing the transplant cells.

    摘要翻译： 根据本发明，提供了一种具有由Sertoli细胞的外壁限定的生物室的生物室系统。 还提供了包括生物室的移植促进剂。 还提供了通过共培养促进细胞和治疗细胞然后聚集辅助细胞来制备生物体的方法。 还提供了通过将移植细胞并入生物室并移植含有移植细胞的生物室来移植细胞的方法。

    Nanoparticle targeted drug delivery to the lungs using extra-testicular Sertoli cells
    10.
    发明授权
    Nanoparticle targeted drug delivery to the lungs using extra-testicular Sertoli cells 有权
    使用睾丸内Sertoli细胞将纳米颗粒靶向药物递送至肺

    公开(公告)号：US09161901B2

    公开(公告)日：2015-10-20

    申请号：US12918265

    申请日：2009-02-23

    申请人： Arun Kumar ,  Shyam S. Mohapatra ,  Don F. Cameron

    发明人： Arun Kumar ,  Shyam S. Mohapatra ,  Don F. Cameron

    IPC分类号： A61K35/48 ,  A61K9/00 ,  A61B5/00 ,  A61K9/50 ,  A61K9/51 ,  A61K31/12 ,  A61K47/36 ,  A61K47/46 ,  A61K47/48 ,  A61K49/00 ,  B82Y5/00

    CPC分类号： A61K31/12 ,  A61B5/0071 ,  A61B5/4848 ,  A61K9/0019 ,  A61K9/5068 ,  A61K9/5161 ,  A61K47/36 ,  A61K47/46 ,  A61K47/61 ,  A61K47/6901 ,  A61K47/6939 ,  A61K49/0043 ,  A61K49/0093 ,  A61K49/0097 ,  B82Y5/00 ,  C12N5/0683

    摘要： A method of delivering a compound of interest to the lungs of a subject by the intravenous injection of Sertoli cells loaded with a plurality of chitosan nanoparticles coupled with the compound of interest is provided. Testis-derived rat Sertoli cells were pre-loaded with chitosan nanoparticles coupled with or without the drug curcumin, pre-labeled with a fluorescent cell marker and then injected intravenously into the control or asthmatic mouse model host. Intact pre-loaded, pre-labeled Sertoli cells were present in the lungs at 15 minutes post-injection, appeared entrapped in the pulmonary pre-capillary vascular bed around alveolar sacs but were not present one hour post-injection although Sertoli cell label and cellular debris was. Most of the injected nanoparticle load (70%) and curcumin load (80%) was present in the lungs 15 minutes post-injection, and remained at 70% and 80%, respectively, one hour post-injection.

    摘要翻译： 提供了通过静脉内注射负载有与感兴趣的化合物结合的多个壳聚糖纳米颗粒的Sertoli细胞将感兴趣的化合物递送到受试者的肺的方法。 睾丸衍生的大鼠支持细胞预先装载有或不含药物姜黄素的壳聚糖纳米颗粒，用荧光细胞标记物预先标记，然后静脉内注射到对照或哮喘小鼠模型宿主中。 完整的预加载，预先标记的Sertoli细胞在注射后15分钟存在于肺中，似乎被夹带在肺泡囊周围的肺前毛细血管血管床中，但注射后1小时不存在，尽管Sertoli细胞标记和细胞 碎片是。 在注射后15分钟，大部分注射的纳米粒子负载（70％）和姜黄色素负荷（80％）分别存在于肺中，并且在注射后1小时分别保持在70％和80％。